Tag Archives: AXIM Biotechnologies

2 Metrics All Cannabis Stock Investors Need to Know

2 Metrics All Cannabis Stock Investors Need to Know

2 Metrics All Cannabis Stock Investors Need to Know

Marijuana stock investors are going to have to keep their eyes on the following two critical data points for each and every marijuana stock they’re considering buying, or that they already own.

Flickr / Jen Montgomery / (CC BY-NC-ND 2.0)

The Average Marijuana Stock Is Up 332% Over the Past Year

Over the trailing-12-month period through July 15, the average marijuana stock with a market cap in excess of $200 million — a dozen stocks in total, which excluded MedReleaf because it just went public a month ago — was up by 332%.

Axim Biotech - MedChew Rx

AXIM Biotech Files Patent on Controlled Release Chewing Gum to Provide Opioid Addiction Treatment

NEW YORK, June 23, 2017 /Weed Wire/ — AXIM Biotechnologies, Inc. (AXIM Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced that the company filed with the United States Patent and Trademark Office (USPTO) for U.S. Application Serial Number 62/410,469, a patent of invention that involves a chewing gum composition with controlled release of cannabinoids and opioid agonists and/or antagonists for addiction and/or dependence treatment.

SeeThruEquity RSHO Raúl Elizalde

SeeThruEquity Initiates Coverage On Medical Marijuana, Inc. Investment Company AXIM Biotech (OTC: AXIM) With A Target Price Of $17.00

SAN DIEGO, Calif., May 17, 2017 /Weed Wire/ — Medical Marijuana, Inc. (OTC PINK:MJNA), the first-ever publicly traded cannabis company in the United States, announced today that its investment company AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC: AXIM) received coverage initiation from SeeThruEquity, a leading independent equity research firm focused on smallcap and microcap public companies, with a price target of $17.00.

Axim Biotech - MedChew Rx

AXIM Biotech Receives Schedule 1 Permit to Move Forward With Development of MedChew Rx Pharmaceutical Chewing Gum

NEW YORK, May 02, 2017 /Weed Wire/ — AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced that the company’s product development partner Quay Pharmaceuticals Ltd. (“Quay Pharma”) has obtained the relevant licenses from the British Home Office to import and work with the controlled drugs that are required to continue the development of AXIM’s MedChew Rx® pharmaceutical chewing gum’s family of products.

These 5 Marijuana Stocks Lost a Combined $193 Million in 2016

These 5 Marijuana Stocks Lost a Combined $193 Million in 2016

These 5 marijuana stocks lost a combined $193 Million in 2016. Though they’re some of the top performers, they’re also among the companies losing the most money on an annual basis.

SeeThruEquity RSHO Raúl Elizalde

Medical Marijuana, Inc. Major Investment AXIM Biotech Enters Term Sheet Agreement With U.S. API Company To Develop Bioequivalent Product To Marinol

SAN DIEGO, Calif., March 28, 2017 /Weed Wire/ — Medical Marijuana, Inc. (OTC: MJNA), the first-ever publicly traded cannabis company in the United States, announced today that its major investment company AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTCQB: AXIM), has entered into a Term Sheet Agreement with a U.S.-based controlled-substances API (Active Pharmaceutical Ingredient) production company to develop a dronabinol-based functional, controlled-release chewing gum product based on AXIM IP and technology.

SeeThruEquity RSHO Raúl Elizalde

Medical Marijuana, Inc. Investment Axim Biotech Announces Enrolled Patients Begin Phase II Trial for the Treatment of Irritable Bowel Syndrome (IBS) with CanChew Plus Cannabidiol (CBD) Chewing Gum

NEW YORK, March 7, 2017 /Weed Wire/ — Medical Marijuana, Inc. (OTC: MJNA), the first-ever publicly traded cannabis company in the United States, announced today that its major investment company AXIM® Biotechnologies, Inc. (AXIM® Biotech) (AXIM) has enrolled 40 patients and commenced its Phase II clinical trial for the treatment of irritable bowel syndrome (IBS) with the company’s CanChew Plus® CBD gum.

Axim Biotech - MedChew Rx

AXIM Biotech Enters IBS Clinical Trial for Canchew CBD Chewing Gum

NEW YORK, Jan. 18, 2017 /Weed Wire/ — AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC: AXIM), a world leader in cannabinoid research and development, has entered clinical trials on treating irritable bowel syndrome (IBS) with the Company’s CanChew Plus® cannabidiol (CBD) gum at Wageningen University in the Netherlands.

SeeThruEquity RSHO Raúl Elizalde

Medical Marijuana, Inc.’s Investment Axim(R) Biotech Files IP Application on Proprietary Method to Extract High-Purity THC

SAN DIEGO, Nov. 29, 2016 /Weed Wire/ — Medical Marijuana, Inc. (OTC PINK: MJNA), the first-ever publicly traded cannabis company in the United States, announced today that its major investment company AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC PINK: AXIM) has filed an IP application with the World Intellectual Property Organization.

CFN MediaGroup

CFN Media Examines Medical Marijuana, Inc.’s Investment in AXIM Biotechnolgies’ Groundbreaking CBD and CBG Research

REDONDO, Calif., July 14, 2016 /Weed Wire/ — CFN Media Group, the leading creative agency and digital media network dedicated to legal cannabis, announces the publication of an article and interview discussing Medical Marijuana Inc.’s (OTC PINK: MJNA) major investment in AXIM Biotechnologies.


Top